ERBB2 and cancer: In a pan-cancer study with 16,847 samples, Li et al. (2022) [44] explored the expression, potential mechanisms, and clinical significance of BCAT1. BCAT1 was predominantly expressed in ERα-negative/HER-2-positive breast cancer and TNBC, and its overexpression enhanced the capacity of antiestrogen-sensitive cells to grow in the presence of antiestrogens [44].